BCL2 and acute lymphoblastic leukemia: Further, we addressed anti-leukemia activity of combined BCL-2 and OxPhos inhibition in a series of PDX BCP-ALL samples characterized by different VEN-sensitivities titrating a dose-response matrix with combinations of increasing concentrations of VEN or Oligomycin.